股票代码：300016 股票简称：北陆药业 公告编号：2025-116 北京北陆药业股份有限公司 关于获得碘美普尔注射液《药品注册证书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，北京北陆药业股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的碘美普尔注射液《药品注册证书》。现将相关情况公告如 下： 一、药品的基本情况 主要成份：碘美普尔 药品通用名称：碘美普尔注射液 剂型：注射剂 规格：100ml:40g(I) 注册分类：化学药品 4 类 药品有效期：24 个月 包装规格：1 瓶/盒，10 瓶/盒 处方药/非处方药：处方药 证书编号：2025S03295 药品注册标准编号：YBH27532025 药品批准文号：国药准字 H20255838 药品批准文号有效期：至 2030 年 11 月 03 日 上市许可持有人名称：北京北陆药业股份有限公司 上市许可持有人地址：北京市密云区水源西路 3 号 生产企业名称：北京北陆药业股份有限公司 1 生产企业地址：北京市密云区水源西路 3 号 受理号：CYHS2401810 公司控股子公司浙江 ...

Market Overview - The precision medicine sector experienced a decline of 1.77% on November 4, with TuoJing Life leading the drop [1][2] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances in the precision medicine sector included: - RenDu Bio (688193) closed at 52.90, up 1.05% with a trading volume of 7076.23 hands and a transaction value exceeding 36.99 million yuan [1] - TuoJing Life (300642) closed at 22.73, down 2.86% with a trading volume of 78,200 hands and a transaction value of 178 million yuan [2] - Other companies like DaAn Gene (002030) and Anke Bio (300009) showed minimal changes, with DaAn Gene remaining flat at 6.57 and Anke Bio down 0.55% to 10.84 [1][2] Capital Flow - The precision medicine sector saw a net outflow of 979 million yuan from institutional investors, while retail investors contributed a net inflow of 642 million yuan [2][3] - Specific stock capital flows indicated: - GuoMai Technology (002093) had a net inflow of 8.61 million yuan from institutional investors, while retail investors saw a net outflow of 15.98 million yuan [3] - TuoJing Life experienced minimal net inflow from institutional investors at 25,000 yuan, with retail investors also showing a slight outflow [3]

人民财讯10月29日电，北陆药业（300016）10月29日公告，公司参加了国家组织药品联合采购办公室组 织的第十一批全国药品集中采购投标工作，公司钆布醇注射剂拟中选。 ...

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) announced that its Gadobutrol injection has been selected for the 11th batch of national centralized drug procurement, which is expected to enhance the company's market share and brand influence in the contrast agent segment [1] Group 1: Product Approval and Sales Performance - The Gadobutrol injection received its drug registration certificate in April 2022 and the supplementary application approval in April 2024 [1] - The sales amount for the product in 2024 is 4.6859 million yuan, accounting for 0.48% of the company's total revenue for that year [1] - For the first three quarters of 2025, the sales amount reached 5.7854 million yuan, representing 0.67% of the company's revenue during that period [1] Group 2: Market Opportunities and Uncertainties - The execution of the procurement results is expected to rapidly open up the market for the Gadobutrol injection [1] - There are uncertainties regarding the signing of procurement contracts and the market sales execution following the centralized procurement [1] - The company will closely monitor the developments and disclose information in a timely manner [1]

股票代码：300016 股票简称：北陆药业 公告编号：2025-114 北京北陆药业股份有限公司 关于钆布醇注射剂拟中选第十一批全国药品集中采购的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，北京北陆药业股份有限公司（以下简称"公司"） 参加了国家组 织药品联合采购办公室（以下简称"联采办"）组织的第十一批全国药品集中 采购投标工作，公司钆布醇注射剂拟中选。现将相关情况公告如下： 二、对公司的影响 公司拟中选产品钆布醇注射剂于 2022 年 4 月、2024 年 4 月分别获得国家 1 中标企业 药品通用名 适应症 申报品规 计价 单位 拟中选价 （元） 拟主供应 省份 北京北陆药业 股份有限公司 钆布醇注射剂 用于诊断，仅供静脉内 给药。全身各部位（包 括颅脑和脊髓）病变的 对比增强磁共振成像 (CE-MRI)检查；对比 增强磁共振血管造影 (CE-MRA)检查。 7.5ml： 4.5354g 瓶 45.84 辽 宁 、 湖 北、广西、 内蒙古、重 庆、宁夏 一、拟中选产品基本情况 药品监督管理局核准签发的《药品注册证书》及《药品补充申请批准通 ...

Core Insights - Northland Pharmaceutical (300016.SZ) released its Q3 2025 report, indicating a total of 52.656 million A-shares held by three institutional investors, accounting for 9.35% of the company's total share capital [1] Institutional Holdings - The total institutional holding percentage decreased by 2.44 percentage points compared to the previous quarter [1] - The institutional investors include Chongqing Three Gorges Paint Co., Ltd., China Resources Yukun Asset Management Co., Ltd., and Guolian Medical Health Mixed A [1] Public Fund Holdings - One public fund, Guolian Medical Health Mixed A, reported a slight decrease in holdings compared to the previous quarter [1] - Ten public funds that did not disclose holdings this quarter include notable names such as PICC Trend Selection Mixed A, Wanji Entrepreneur Board Comprehensive ETF, and Southern CSI 2000 ETF [1] Foreign Investment - Several foreign institutions, including BARCLAYS BANK PLC, MORGAN STANLEY & CO. INTERNATIONAL PLC, and Goldman Sachs LLC, did not disclose their holdings this quarter [1]

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) reported a significant increase in revenue and net profit for the first three quarters of 2025, indicating strong financial performance and growth potential [1] Financial Performance - The company's operating revenue for the first three quarters reached 873 million yuan, representing a year-on-year growth of 19.59% [1] - The net profit attributable to shareholders of the listed company was 44.1769 million yuan, showing a year-on-year increase of 81.10% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 33.6758 million yuan, reflecting a year-on-year growth of 33.53% [1] - Basic earnings per share were reported at 0.087 yuan [1]

Core Viewpoint - Beilu Pharmaceutical (300016) announced that neither the company nor its controlling and wholly-owned subsidiaries have any violations regarding guarantees or overdue guarantees, and there are no external guarantees involved in lawsuits or losses due to guarantee judgments [1] Summary by Categories - **Company Compliance** - The company confirmed no violations in guarantees or overdue guarantees [1] - There are no external guarantees related to lawsuits or losses from guarantee judgments [1]

Group 1 - The core viewpoint of the article highlights that Beijing Beilu Pharmaceutical Co., Ltd. reported significant growth in revenue and net profit for the first three quarters of 2025, with revenue reaching 873 million yuan, a year-on-year increase of 19.59%, and net profit attributable to shareholders amounting to 44.18 million yuan, up 81.10% [1][2] - The growth in net profit is attributed to multiple factors, including the company's ongoing efforts in standardizing products for centralized procurement and actively promoting non-procurement products and overseas market sales, which contributed to stable revenue growth [1] - The completion of the conversion of "Beilu Convertible Bonds" led to reduced interest expenses, positively impacting net profit metrics [1] Group 2 - Beilu Pharmaceutical's subsidiary, Haichang Pharmaceutical, achieved significant progress in research and registration, including the approval of iodinated contrast agents for market entry in various countries, which lays a foundation for expanding domestic and international markets [1] - The company plans to continue its dual-driven strategy of "chemical drugs + traditional Chinese medicine," focusing on both domestic and overseas markets to enhance profitability and overall competitiveness [2]

Core Insights - Beilu Pharmaceutical (300016) reported strong performance in Q3 2025, with revenue reaching 873 million yuan, a year-on-year increase of 19.59%, and net profit attributable to shareholders at 44.18 million yuan, up 81.10% [1] - The growth in net profit was driven by the implementation of centralized procurement products and expansion in non-centralized procurement products and overseas markets [1] - The company plans to raise up to 300 million yuan through a simplified procedure for issuing shares to specific investors, aimed at funding various projects and supplementing working capital [2] Financial Performance - For the first three quarters of 2025, Beilu Pharmaceutical achieved operating revenue of 873 million yuan, a 19.59% increase year-on-year [1] - Net profit attributable to shareholders was 44.18 million yuan, reflecting an 81.10% increase compared to the previous year [1] - The net profit excluding non-recurring gains and losses was 33.68 million yuan, up 33.53% year-on-year [1] Strategic Developments - The company is focusing on a dual-driven strategy of "chemical drugs + traditional Chinese medicine" while enhancing its presence in both domestic and international markets [2] - Significant progress was made by the subsidiary Haichang Pharmaceutical, including the approval of several chemical raw materials and obtaining market access in Korea and India [2] - The funds raised will support the construction of new production lines and enhance the company's operational capabilities [2]